Drugs that contain Dextroamphetamine
1. Xelstrym patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8591941 | NOVEN PHARMS INC | Transdermal drug delivery device including an occlusive backing |
Oct, 2025
(1 year, 5 months from now) | |
| US9034370 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(1 year, 5 months from now) | |
| US8632802 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(1 year, 5 months from now) | |
| US9474722 | NOVEN PHARMS INC | Compositions and methods for transdermal delivery of amphetamine |
Oct, 2033
(9 years from now) | |
| US9456993 | NOVEN PHARMS INC | Compositions and methods for transdermal delivery of amphetamine |
Oct, 2033
(9 years from now) | |
| US11559501 | NOVEN PHARMS INC | Transdermal amphetamine compositions with low levels of carbamate |
Jan, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2025 |
Market Authorisation Date: 22 March, 2022
Treatment: A method of treating attention deficit hyperactivity disorder by administering a transdermal composition containing amphetamine
Dosage: SYSTEM;TRANSDERMAL
More Information on Dosage
XELSTRYM family patents
